Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Operating Income (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Operating Income for 7 consecutive years, with -$6.1 million as the latest value for Q1 2026.

  • For Q1 2026, Operating Income rose 70.51% year-over-year to -$6.1 million; the TTM value through Mar 2026 reached -$56.0 million, up 21.81%, while the annual FY2025 figure was -$70.6 million, 3.8% down from the prior year.
  • Operating Income hit -$6.1 million in Q1 2026 for Barinthus Biotherapeutics, up from -$11.6 million in the prior quarter.
  • Across five years, Operating Income topped out at $13.2 million in Q2 2022 and bottomed at -$26.3 million in Q2 2023.
  • Average Operating Income over 5 years is -$13.7 million, with a median of -$16.9 million recorded in 2024.
  • Year-over-year, Operating Income surged 230.71% in 2022 and then plummeted 3385.02% in 2023.
  • Barinthus Biotherapeutics' Operating Income stood at -$25.1 million in 2022, then rose by 20.34% to -$20.0 million in 2023, then decreased by 17.02% to -$23.4 million in 2024, then skyrocketed by 50.56% to -$11.6 million in 2025, then surged by 47.47% to -$6.1 million in 2026.
  • According to Business Quant data, Operating Income over the past three periods came in at -$6.1 million, -$11.6 million, and -$15.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.